Categories: News

Rapid Micro Biosystems to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

LOWELL, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15th, 2021.

Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a virtual 30-minute question-and-answer session with the host analyst beginning at 5:00am Pacific Time/8:00am Eastern Time. A live webcast of the session will be available on the Company’s website at https://investors.rapidmicrobio.com/. The webcast will then be archived and available for replay for 90 days after the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company’s flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct platform brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn.

CONTACT: Investor Contact:
David Deuchler
Gilmartin Group LLC
investors@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

Staff

Recent Posts

This World Cancer Day, St. Baldrick’s Foundation Leads the Charge Against Childhood Cancer

Los Angeles, California--(Newsfile Corp. - February 4, 2026) - This World Cancer Day, the St.…

19 minutes ago

The Leadership Shift Powering Doceree’s Next Chapter in the US: Kamya Elawadhi Announced as Co-Founder & President

Strategic elevation signals bold expansion as Doceree redefines healthcare marketing with AI-powered precision and purposeSHORT…

2 hours ago

Canvas Medical Named 2026 Best in KLAS for Ambulatory Specialty EHR

Next-generation EMR platform recognized for helping specialty practices deliver efficient, personalized patient careSAN FRANCISCO, Feb.…

2 hours ago

Kontakt.io Introduces Supply Chain AI to Transform Care Support Operations

Agentic AI integrates EHR and RTLS data to automate equipment workflows and improve operational efficiency,…

2 hours ago

Robotic Surgery Market Is No Longer a Technology Story. It Is a Discipline Test for Hospitals: MMR Statistics

PUNE, India, Feb. 4, 2026 /PRNewswire/ -- For nearly a decade, robotic surgery was sold as progress.…

2 hours ago

Champion Insights Officially Opens Enrollment to Investigate ALS Risk in High-Performance Athletes, Military Members, and First Responders

Ambitious nationwide study will enroll 500 participants to examine genetic, biological, and environmental factors linked…

2 hours ago